McFarland Laboratory

05/03/2021

We are very excited for our first publication with and Janaina on her exciting project aimed at modifying amyloid-beta peptide aggregation with photoactive metal complexes!

https://pubs.rsc.org/en/Content/ArticleLanding/2021/SC/D1SC00004G #!divAbstract

12/10/2020

Check out Photodynamic Inc (Dr. Sherri McFarland founded this company) on Facebook. https://www.facebook.com/PhytoLight

PhytoLight a new breakthrough oral hygiene technology.
Prevents calculus & promotes healthy gums.

11/23/2020

More exciting November news! We are excited that our TLD-1433 has been granted FDA fast track status!

"The accelerated communication with the FDA potentially allows, TLD-1433, in combination with the TLC-3200 medical laser system (“TLC-3200”), to be the first intravesical patient-specific Ruthenium-based PDC for the treatment of patients with BCG-Unresponsive NMIBC CIS, with or without papillary Ta or T1 tumours."

Press release content from Accesswire. The AP news staff was not involved in its creation.

11/14/2020

Some November updates:

Theralase Technologies (Toronto, Canada), is currently underway with their lead compound, TLD-1433 (invented in McFarland Labs), into Phase II Non Muscle Invasive Bladder Cancer (“NMIBC”) clinical study for Bacillus Calmette-Guérin (“BCG”)-unresponsive patients at 4 Canadian clinical study sites.

But here is even more exciting news!!! TLD-1433 has now shown remarkable high-kill rate in a preclinical analysis of Coronavirus BSL-2!! (note: this is not Covid-19 strain which is caused by BSL-3 virus).

The Company has signed an agreement with a Trial Management Organization to provide 4 to 6 US based urology study sites that will be able to commence enrolling and treating patients

10/23/2020

We are also on Twitter!

The latest Tweets from McFarland Laboratory (): "Bis[pyrrolyl Ru(ii)] triads: a new class of photosensitizers for metal–organic photodynamic therapy - now published in Chemical Science https://t.co/E36KszAdML "

10/08/2020

Another new journal article, a collaboration between the McFarland lab and Dr. Allison Thompson group at Dalhousie University!

09/30/2020

Ongoing news from our lab!

The researchers decided to use metals because when humans carry out a sophisticated reaction involving the transferring of electrons a metal in the protein is what allows said transfer.

09/24/2020

Check out our new publication!
Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy!!

Hypoxia presents a two-fold challenge in the treatment of cancer, as low oxygen conditions induce biological changes that make malignant tissues simultaneously more aggressive and less susceptible to standard chemotherapy. This paper reports the first metal-based photosensitizer that approaches the....

09/17/2020

Read some of our latest announcements!
"An international team of chemistry researchers led by The University of Texas at Arlington has published a study which details the discovery of a compound that shows great promise as a weapon in the fight against cancer."

The College of Science at The University of Texas at Arlington offers world class education and research programs in Biology, Chemistry and Biochemistry, Earth and Environmental Sciences, Mathematics, Physics, and Psychology.

08/28/2020

Our awesome research group meets virtually after a productive week

10/05/2018

Dear Cancer Sucks Halloween Howl Group,
We thank you, in advance, of your generous support of this most worthy annual event. We want to share some of our research news with you, it’s been an exciting busy year!
Our most exciting news is that our lead compound TLD1433 has successfully completed a Phase I human clinical trial this year! You may remember that, in 2017, this compound entered a trial to investigate the treatment on patients with Non-Muscle Invasive Bladder Cancer (“NMIBC”). Funding has now been secured to proceed to a much larger Phase II clinical trial, which will involve approximately 100 NMIBC patients. To find out more about this amazing ongoing research:

Theralase® a biotech company in Canada is pleased to announce Health Canada has approved the Company’s Clinical Trial Application (“CTA”), allowing clinical study evaluation of Theralase’s lead anti-cancer drug, TLD-1433. Press release on Sept 10, 2018